SG Americas Securities LLC Buys 49,356 Shares of Insmed, Inc. $INSM

Key Points

• SG Americas Securities LLC boosted its stake in Insmed by 283.6%, buying 49,356 shares to hold 66,762 shares worth about $11.62 million at the end of the quarter.
• Sell-side sentiment is broadly positive with an average target price of $210.19 and most analysts rating the stock "Buy" (3 Strong Buy, 19 Buy, 1 Hold, 1 Sell), while several firms raised targets though Wells Fargo cut its target to $175.
• Insider selling was significant last quarter—insiders sold 189,651 shares totaling roughly $31.53 million (including large sales by Orlov and CEO William Lewis), and insiders now own about 3% of the company.

SG Americas Securities LLC increased its position in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) by 283.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 66,762 shares of the biopharmaceutical company's stock after purchasing an additional 49,356 shares during the quarter. SG Americas Securities LLC's holdings in Insmed were worth $11,619,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the company. CIBC Private Wealth Group LLC lifted its holdings in shares of Insmed by 42.1% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 53 shares during the period. Stone House Investment Management LLC bought a new position in Insmed in the third quarter valued at approximately $29,000. SBI Securities Co. Ltd. raised its position in Insmed by 404.9% during the third quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 166 shares in the last quarter. MassMutual Private Wealth & Trust FSB raised its position in Insmed by 59.6% during the third quarter. MassMutual Private Wealth & Trust FSB now owns 217 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 81 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. lifted its stake in Insmed by 169.7% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 240 shares of the biopharmaceutical company's stock worth $38,000 after purchasing an additional 151 shares during the last quarter.

Analysts Set New Price Targets

Several brokerages have recently issued reports on INSM. Royal Bank Of Canada lifted their price target on Insmed from $197.00 to $200.00 and gave the company an "outperform" rating in a research note on Wednesday, January 21st. HC Wainwright raised their price objective on Insmed from $230.00 to $245.00 and gave the company a "buy" rating in a research note on Thursday. TD Cowen set a $241.00 target price on Insmed in a research report on Thursday, December 18th. Stifel Nicolaus boosted their target price on Insmed from $205.00 to $208.00 and gave the stock a "buy" rating in a research note on Tuesday, March 24th. Finally, Wells Fargo & Company dropped their target price on shares of Insmed from $208.00 to $175.00 and set an "overweight" rating for the company in a report on Monday, March 23rd. Three analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Insmed has an average rating of "Buy" and an average target price of $210.19.

Insmed Trading Down 1.6%

NASDAQ INSM opened at $145.30 on Friday. The company has a market cap of $31.32 billion, a price-to-earnings ratio of -22.67 and a beta of 1.13. Insmed, Inc. has a twelve month low of $60.40 and a twelve month high of $212.75. The company has a quick ratio of 3.54, a current ratio of 3.83 and a debt-to-equity ratio of 0.76. The business's fifty day moving average is $150.13 and its 200 day moving average is $166.10.

Insmed (NASDAQ:INSM - Get Free Report) last posted its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) EPS for the quarter, missing the consensus estimate of ($1.07) by ($0.47). Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. The firm had revenue of $263.84 million during the quarter, compared to the consensus estimate of $263.97 million. During the same quarter in the prior year, the business posted ($1.32) earnings per share. Insmed's revenue for the quarter was up 152.6% compared to the same quarter last year. As a group, sell-side analysts expect that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Orlov S. Nicole Schaeffer sold 87,290 shares of Insmed stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $175.20, for a total transaction of $15,293,208.00. Following the sale, the insider directly owned 41,754 shares in the company, valued at $7,315,300.80. This trade represents a 67.64% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO William Lewis sold 19,215 shares of the business's stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $169.00, for a total transaction of $3,247,335.00. Following the sale, the chief executive officer directly owned 306,891 shares in the company, valued at $51,864,579. The trade was a 5.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 189,651 shares of company stock valued at $31,533,654. 3.00% of the stock is owned by company insiders.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company's principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.